Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial

Tocilizumab has been reported to attenuate the “cytokine storm” in COVID-19 patients. We attempted to verify the effectiveness and safety of tocilizumab therapy in COVID-19 and identify patients most likely to benefit from this treatment. We conducted a randomized, controlled, open-label multicenter...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Dongsheng, Fu, Binqing, Peng, Zhen, Yang, Dongliang, Han, Mingfeng, Li, Min, Yang, Yun, Yang, Tianjun, Sun, Liangye, Li, Wei, Shi, Wei, Yao, Xin, Ma, Yan, Xu, Fei, Wang, Xiaojing, Chen, Jun, Xia, Daqing, Sun, Yubei, Dong, Lin, Wang, Jumei, Zhu, Xiaoyu, Zhang, Min, Zhou, Yonggang, Pan, Aijun, Hu, Xiaowen, Mei, Xiaodong, Wei, Haiming, Xu, Xiaoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Higher Education Press 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940448/
https://www.ncbi.nlm.nih.gov/pubmed/33687643
http://dx.doi.org/10.1007/s11684-020-0824-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940448/
https://www.ncbi.nlm.nih.gov/pubmed/33687643
http://dx.doi.org/10.1007/s11684-020-0824-3

Ejemplares similares